Avascular Necrosis Market Research Report – Forecast to 2027

Global  Avascular  Necrosis  Market  Research  Report  By  Type  (Trauma  Related  Avascular  Necrosis  (AVN)  and  Non-Trauma  Related  Avascular  Necrosis  (AVN),  By  Site  (Hip  Bone,  Knee,  Shoulder  and  Other),  By  Diagnosis(Imaging,  Biopsy,  Total,  CT  Scan,  PET  and  X-  Ray),  By  Treatment  (Medication,  Electrical  Stimulation,  Gene  Therapy  and  Surgery),  By  End-User(Hospitals  &  Clinics,  Diagnostic  Centers  and  Ambulatory  Surgical  Centers),  By  Region  –  Forecast  to  2027.

ID: MRFR/MED/4673-CR | June 2018 | Region: Global | 539 pages

Please note that the assessment period of report has been updated from 2018-2024 to 2020-2027. Cordially fill the sample form for updated data.

Market Snapshot


The global avascular necrosis market is set to expand at 6.58% CAGR during 2018 to 2024. The demand for avascular necrosis treatment has witnessed a healthy uptick in recent years. This is attributable to factors such as the increased bone disorder burden worldwide and the rising global geriatric population.  Changing lifestyle, increased prevalence of alcoholism and steroid use, especially among young adults and middle-aged individuals are other popular factors linked with the upsurge in avascular necrosis occurrence. Meanwhile, healthcare providers remain focused on providing low cost treatment to penetrate regional markets that have higher representation of price-sensitive patients. China and India currently account for nearly 40% of the total global population affected by AVN. These two countries present lucrative market opportunities, however, unstructured regulatory frameworks and lack of awareness are some of major blockades faced by healthcare providers in creating a wider access to medical care in these two countries.


Report Overview


This MRFR report delivers a detailed perspective on the global market for avascular necrosis. In-depth information on the market pertaining to historical market trends and current market scenario along with market forecast for the next six years is offered in the report. Key macro and micro-economic factors affecting the global avascular necrosis market were also discussed.


The report includes analysis of types of avascular necrosis, disease site, diagnosis, treatment, and end-user. Based on types, into trauma-related avascular necrosis (AVN) and non-trauma related avascular necrosis (AVN) were considered for market sizing. Hip bone, knee, and shoulder were the prominent disease sites discussed in the report for market valuation. The market share captured by imaging diagnosis and biopsy diagnosis was also examined. Based on treatment, medication, electrical stimulation, gene therapy, and surgery made up for the overall market size. Based on end user, the key market segments covered in the report include hospitals & clinics, diagnostic centers, and ambulatory surgical centers. All the segments and sub-segments are profiled under five major regions–North America, Latin America, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA), with the respective country-level market sizes. The report analyses the current and future prospect of the market and delivers an unbiased growth assessment.


Players Covered


Stryker Corporation, Medtronic plc, Ethicon Inc., Sanofi SA, Bayer AG, Pfizer Inc., Merck KGaA, Boehringer Ingelheim GmbH, Eli Lilly and Company, Aurobindo Pharma, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Wright Medical Group N.V., Grifols SA, and Smith and Nephew.


Research Methodology


To preserve integrity and objectivity in our research we have used a carefully compiled body of methods. Our data analysts collect data based on primary and secondary research methods to provide validated reports with close estimations, which reflect the state of the market with high accuracy. Primary data collection methods include interviews with key level executives of the relevant industry, while secondary data collection methods include the use of credible sources. Market size validation and estimations pertaining to the forecast period have been made after utilizing top-down and bottom-up approaches for unsurmountable reliability. Our reports provide valuable insights that allow stakeholders to make decisions with confidence.


Analysis Period



  • Base Year- 2017

  • Projection Period- From 2018 to 2024

  • Market valuation- USD Million

  • Conversion Rate- Considered as per the respective financial years


Intended Audience



  • Avascular necrosis (AVN) manufacturers

  • Suppliers and distributors

  • Potential investors

  • Raw material suppliers

  • Pharmaceutical companies

  • Associations

  • Government

  • End-Users


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for avascular necrosis (AVN).


By Type



  • Trauma-Related Avascular Necrosis (AVN)

  • Non-Trauma Related Avascular Necrosis (AVN)


By Site



  • Hip Bone

  • Knee

  • Shoulder

  • Other


By Diagnosis



  • Imaging

  • Biopsy


By Treatment



  • Medication

  • Electrical Stimulation

  • Gene Therapy

  • Surgery


By End-User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Ambulatory Surgical Centers


By Region



  • Americas; North America (the U.S., and Canada),

  • Latin America

  • Europe; Western Europe (Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe, Eastern Europe

  • Asia Pacific (APAC); Japan, China, India, Australia, Republic of Korea and Rest of Asia Pacific

  • The Middle East & Africa (MEA); Middle East & Africa



Frequently Asked Questions (FAQ) :


Projected Avascular Necrosis Market CAGR would be 6.58% during the forecast period of 2020 to 2027.

The players taking part are Medtronic plc, Ethicon Inc., Stryker Corporation, Bayer AG, Sanofi SA, Merck KGaA, Pfizer Inc., Eli Lilly and Company, Aurobindo Pharma, Boehringer Ingelheim GmbH, Zimmer Biomet Holdings, Integra LifeSciences Corporation, Grifols SA, Wright Medical Group N.V., and Smith and Nephew.

Avascular Necrosis Market valuation would be USD 1.12 billion by 2024.

Strict government regulations would hold back Avascular Necrosis Market growth.

The Imaging segment would lead Avascular Necrosis Market.

The global avascular necrosis (AVN) market, is set to reach an approximate evaluation of USD 1.12 Bn by the end of 2024 and experience a modest CAGR of 6.58% during the forecast period of 2018 to 2024. This projects a cautious upward trend which is driven by the considerable growth of the pharmaceutical sector in rapidly emerging economies.


Known by other names such as osteonecrosis or bone infarction, the condition is gaining global awareness thus supporting the growth of the AVN market. The disease which more commonly afflicts men between the ages of 30 to 50 years, has been highly prevalent in emerging economies. Additionally, the rising cases of long-term steroid and alcohol abuse have further contributed to the prevalence of the disease. The eventual requirement of surgery and the widespread use of medication to control the symptoms of AVN is another factor driving sales of drugs such as non-steroidal anti-inflammatory drugs. This factor is also responsible for the increased demand for alternative treatment options such as minimally invasive surgery. Moreover, osteonecrosis is challenging to diagnose, and there is no known cure, which has increased R&D focus on treatment alternatives outside of surgery. 


Stringent government regulations aimed at improving quality of medical implants are adversely affecting the cost of the market making surgery unaffordable for many patients. This restrains entry into the market as smaller players are unable to compete with established market leaders as well as comply with regulations. Additionally, the high cost of orthopedic surgeries is due to the complexity of orthopedic conditions, and there is a shortage of skilled surgeons to perform these surgeries. However, the global pharmaceutical and healthcare sector appears to be booming and is making great strides in research and development of noninvasive treatment options for osteonecrosis. In an effort to meet the high demand for non-surgical treatment alternatives, key players are making investments in the development of such options thus paving new avenues for growth during the forecast period.


The global market for avascular necrosis is segmented on the basis of type, site, diagnosis, treatment, end-user, and region. By type, the market has been segmented into trauma-related avascular necrosis, and non-trauma related avascular necrosis, with the latter having the most significant share of the market due to rising cases of alcoholism and steroid abuse. This segment is expected to remain highly lucrative through the review period.


By site, the market has been segmented into hip bone, knee, shoulder and other. In 2017, the hip segment was valued at over USD 508 Mn and is expected to remain in leading position during the forecast period due to the highest number of cases of AVN being recorded for this particular site. 


By diagnosis, the market has been segmented into imaging and biopsy. The imaging segment, which presently accounts for the largest segment is expected to retain its market-leading position over the assessment period due to the need for early diagnosis of this diseases for effective treatment.


By treatment, the market has been segmented into medication, electrical stimulation, gene therapy and surgery. Surgery is the present leading segment valued at over USD 202.8 Mn and is expected to continue growing due to advancing surgery techniques and the present need for surgery regarding long-term relief. However, the fastest growing segment during the forecast period is expected to be gene therapy, due to the lack of side effects and increasing advancements in targeted treatment.


By end-user, the market has been segmented into hospitals & clinics, diagnostic centers, and ambulatory surgical centers. Hospitals and clinics segment is expected to maintain its position as the largest segment. The growth of this segment can be attributed to financial pressures and the increase in outsourcing of the diagnosis process. Moreover, surgeries for treatment of this disease are primarily carried out in hospitals and clinics.                       


Regional Analysis


The Americas lead the global market for avascular necrosis due to the presence of various reputable market leaders and the technological advancements in diagnostics in the region. Countries such as U.S. and Canada are leading growth for the Americas. The second largest regional market segment belongs to Europe, due to the presence of a well-developed healthcare sector with favorable policies regarding research and development.


The Asia-Pacific is expected to be the fastest growing market for AVN due to the presence of a vast population with an increased rate of occurrence for osteonecrosis. Moreover, manufacturing of medical devices has shifted prominently to this region due to the ease in availability of cheap labor costs and lower investments in necessary infrastructure.   


Competitive Tracking


In due course of market study, key market-leading players were identified and analyzed including players such as Sanofi, Boehringer Ingelheim, Merck KGaA, Eli Lilly and company, Medtronics Plc, and Pfizer Inc. Other notable players included are Bayer AG, Bristol-Myers Squibb, Zimmer Biomet Holdings, and Integra LifeSciences Corporation among others.


Although entry for small players is restrictive, ongoing innovations and development of relevant and effective treatment are some of the strategies employed by market players to expand market share.

1 Executive Summary

2 Market Introduction

2.1 Scope Of Study 32

2.2 Research Objective 32

2.3 List Of Assumptions 32

2.4 Market Structure 33

3 Research Methodology

3.1 Research Process 35

3.2 Primary Research 36

3.3 Secondary Research 37

3.4 Market Size Estimation 37

3.5 Forecast Model 38

4 Market Dynamics

4.1 Introduction 40

4.2 Drivers 41

4.2.1 Increasing Awareness Along With The High Prevalence Of The Avascular Necrosis Disease 41

4.2.2 Rising Preference Of Surgeries To Cure Osteonecrosis 41

4.2.3 Rising Preference Of Bone Grafting Surgical Procedures With The Less Pain Substitute Procedures 41

4.2.4 Consolidation Of Large Healthcare Providers In The U.S. 42

4.2.5 Technological Advancements In The Development Of Surgical Implants 42

4.3 Restraints 42

4.3.1 The High Cost Of Surgical Procedures And Related Side Effects 42

4.3.2 Worsening Regulatory Landscape And Growing Cost Of Noncompliance In Developed Countries 43

4.4 Opportunities 43

4.4.1 Growing Demand For Non-Invasive Treatments For Faster Recovery 43

4.5 Technology Trends & Assessment 44

4.5.1 Acceptance Of Synthetic Bone-Graft Over Natural Ones 44

4.5.2 Nanotechnology 44

4.5.3 Rising Demand For Incorporating Recombinant DNA Technology In Surgical Implants 44

4.5.4 Development Of Titanium-Foam Implant For Bone Grafting 44

4.5.5 Customized Degradable Implants 44

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 46

5.1.1 Bargaining Power Of Suppliers 46

5.1.2 Bargaining Power Of Buyers 47

5.1.3 Threat Of New Entrants 47

5.1.4 Threat Of Substitutes 47

5.1.5 Intensity Of Rivalry 48

5.2 Value Chain Analysis 48

5.2.1 Research & Development 48

5.2.2 Manufacturing 49

5.2.3 Distribution 49

5.2.4 Marketing & Sales 49

5.2.5 Post-Sales Monitoring 49

5.3 Epidemiology Of Avascular Necrosis 49

6 Avascular Necrosis Market, By Type

6.1 Introduction 54

6.2 Non-Trauma Related Avascular Necrosis 55

6.2.1 Age Group 56

6.2.1.1 Third Decade 57

6.2.1.2 Fifth Decade 57

6.2.2 Causes 58

6.2.2.1 Caisson Disease 59

6.2.2.2 Sickle Cell Anaemia 60

6.2.2.3 Steroid Abuse 60

6.2.2.4 Alcohol Abuse 61

6.3 Trauma-Related Avascular Necrosis 62

7 Avascular Necrosis Market, By Site

7.1 Introduction 64

7.2 Hip Bone 65

7.3 Knee 66

7.4 Shoulder 67

8 Avascular Necrosis Market, By Diagnosis

8.1 Introduction 69

8.2 Imaging 70

8.2.1 X-Ray 72

8.2.2 CT Scan 72

8.2.3 MRI 73

8.2.4 PET 74

8.3 Biopsy 74

9 Avascular Necrosis Market, By Treatment

9.1 Introduction 77

9.2 Medication 78

9.2.1 Medication By NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 79

9.2.2 Medication By Bisphosphonates 79

9.2.3 Medication By Blood Thinners 80

9.3 Electrical Stimulation 81

9.4 Gene Therapy 82

9.5 Surgery 82

9.5.1 Core Decompression 83

9.5.2 Osteotomy 84

9.5.3 Bone Graft 85

9.5.4 Arthoplasty 85

10 Avascular Necrosis Market, By End-User

10.1 Introduction 88

10.2 Hospitals & Clinics 89

10.3 Diagnostic Centers 90

10.4 Ambulatory Surgical Centers 91

11 Global Avascular Necrosis Market, By Region

11.1 Introduction 93

11.2 Americas 103

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.2.1 North America 112

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.2.1.1 U.S. 123

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.2.1.2 Canada. 131

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.2.2 South America 140

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3 Europe 149

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1 Western Europe 160

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.1 Germany 170

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.2 France 179

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.3 UK 188

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.4 Italy 197

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.5 Spain 206

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.1.6 Rest Of Western Europe 215

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.3.2 Eastern Europe 224

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4 Asia Pacific 232

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.1 Japan 243

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.2 China 251

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.3 India 260

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.4 Australia 268

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.5 Republic Of Korea 277

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.4.6 Rest Of Asia Pacific 285

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.5 The Middle East & Africa 294

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.5.1.1 Middle East 303

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

11.5.1.2 Africa 313

Avascular Necrosis Market, By Type

Avascular Necrosis Market, By Site

Avascular Necrosis Market, By Diagnosis

Avascular Necrosis Market, By Treatment

Avascular Necrosis Market, By End-User

12 Competitive Landscape

12.1 Introduction 324

12.2 Company Market Share Analysis 325

12.2.1 Introduction 325

12.3 Key Developments 326

13 Company Profiles

13.1 Sanofi 330

13.1.1 Company Overview 330

13.1.2 Financial Overview 330

13.1.3 Products Offering 331

13.1.4 Key Developments 331

13.1.5 SWOT Analysis 331

13.1.6 Key Strategy 331

13.2 Bayer Healthcare AG 332

13.2.1 Company Overview 332

13.2.2 Financial Overview 332

13.2.3 Products Offering 333

13.2.4 Key Developments 333

13.2.5 SWOT Analysis 333

13.2.6 Key Strategy 333

13.3 Boehringer Ingelheim GmbH 334

13.3.1 Company Overview 334

13.3.2 Financial Overview 334

13.3.3 Products Offering 335

13.3.4 Key Developments 335

13.3.5 SWOT Analysis 335

13.3.6 Key Strategy 335

13.4 Pfizer Inc. 336

13.4.1 Company Overview 336

13.4.2 Financial Overview 336

13.4.3 Products Offering 337

13.4.4 Key Developments 337

13.4.5 SWOT Analysis 337

13.4.6 Key Strategy 337

13.5 Merck KGaA 338

13.5.1 Company Overview 338

13.5.2 Financial Overview 338

13.5.3 Products Offering 339

13.5.4 Key Developments 339

13.5.5 SWOT Analysis 339

13.5.6 Key Strategy 339

13.6 Stryker Corporation 340

13.6.1 Company Overview 340

13.6.2 Financial Overview 340

13.6.3 Products Offering 341

13.6.4 Key Developments 341

13.6.5 SWOT Analysis 342

13.6.6 Key Strategy 342

13.7 Medtronic PLC 343

13.7.1 Company Overview 343

13.7.2 Financial Overview 343

13.7.3 Products Offering 344

13.7.4 Key Developments 344

13.7.5 SWOT Analysis 344

13.7.6 Key Strategy 344

13.8 Aurobindo Pharma 345

13.8.1 Company Overview 345

13.8.2 Financial Overview 345

13.8.3 Products Offering 346

13.8.4 Key Developments 346

13.8.5 SWOT Analysis 347

13.8.6 Key Strategy 347

13.9 Integra LifeSciences Corporation 348

13.9.1 Company Overview 348

13.9.2 Financial Overview 348

13.9.3 Products Offering 349

13.9.4 Key Developments 349

13.9.5 SWOT Analysis 349

13.9.6 Key Strategy 349

13.10 Zimmer Biomet Holdings 350

13.10.1 Company Overview 350

13.10.2 Financial Overview 350

13.10.3 Products Offering 351

13.10.4 Key Developments 351

13.10.5 SWOT Analysis 352

13.10.6 Key Strategy 352

13.11 Wright Medical Group N.V. 353

13.11.1 Company Overview 353

13.11.2 Financial Overview 353

13.11.3 Products Offering 354

13.11.4 Key Developments 354

13.11.5 SWOT Analysis 355

13.11.6 Key Strategy 355

13.12 Grifols SA 356

13.12.1 Company Overview 356

13.12.2 Financial Overview 356

13.12.3 Products Offering 357

13.12.4 Key Developments 357

13.12.5 SWOT Analysis 357

13.12.6 Key Strategy 357

13.13 Smith & Nephew 358

13.13.1 Company Overview 358

13.13.2 Financial Overview 358

13.13.3 Products Offering 359

13.13.4 Key Developments 359

13.13.5 SWOT Analysis 360

13.13.6 Key Strategy 360

13.14 Ethicon Inc. 361

13.14.1 Company Overview 361

13.14.2 Financial Overview 361

13.14.3 Products Offering 362

13.14.4 Key Developments 362

13.14.5 SWOT Analysis 363

13.14.6 Key Strategy 363

14 Conclusion

14.1 Key Findings 365

14.1.1 CEO’s Viewpoint 365

14.1.2 Unmet Needs 365

14.1.3 Key Companies To Watch 365

14.1.4 Prediction 365

15 Appendix

15.1 Discussion Blue Print 367

16 List Of Tables

TABLE 1 MARKET SYNOPSIS 30

TABLE 2 LIST OF ASSUMPTIONS 32

TABLE 3 NORTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50

TABLE 4 NORTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50

TABLE 5 SOUTH AMERICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 50

TABLE 6 SOUTH AMERICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 50

TABLE 7 EUROPE PROCEDURE NUMBERS, 2020–2016 (UNITS) 51

TABLE 8 EUROPE PROCEDURE NUMBERS, 2027–2027 (UNITS) 51

TABLE 9 ASIA PACIFIC PROCEDURE NUMBERS, 2020–2016 (UNITS) 51

TABLE 10 ASIA PACIFIC PROCEDURE NUMBERS, 2027–2027 (UNITS) 51

TABLE 11 MIDDLE EAST PROCEDURE NUMBERS, 2020–2016 (UNITS) 52

TABLE 12 MIDDLE EAST PROCEDURE NUMBERS, 2027–2027 (UNITS) 52

TABLE 13 AFRICA PROCEDURE NUMBERS, 2020–2016 (UNITS) 52

TABLE 14 AFRICA PROCEDURE NUMBERS, 2027–2027 (UNITS) 52

TABLE 15 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 16 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 54

TABLE 17 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 55

TABLE 18 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 19 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 56

TABLE 20 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP,2020–2027 (USD MILLION) 56

TABLE 21 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION 2020–2027 (USD MILLION) 57

TABLE 22 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 23 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 24 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2020–2027 (USD MILLION) 58

TABLE 25 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 58

TABLE 26 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2020–2027 (USD MILLION) 59

TABLE 27 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 28 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 29 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANAEMIA, BY REGION, 2020–2027 (USD MILLION) 60

TABLE 30 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2020–2027 (USD MILLION) 60

TABLE 31 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 60

TABLE 32 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 33 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 34 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 35 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62

TABLE 36 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2020–2027 (USD MILLION) 62

TABLE 37 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 64

TABLE 38 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020–2027 (USD MILLION) 65

TABLE 39 GLOBAL AVASCULAR NECROSIS MARKET FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 65

TABLE 40 GLOBAL AVASCULAR NECROSIS MARKET, FOR HIP BONE, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 41 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 42 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2020–2027 (USD MILLION) 66

TABLE 43 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67

TABLE 44 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2020–2027 (USD MILLION) 67

TABLE 45 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69

TABLE 46 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020–2027 (USD MILLION) 69

TABLE 47 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 70

TABLE 48 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2020–2027 (USD MILLION) 71

TABLE 49 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71

TABLE 50 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020–2027 (USD MILLION) 71

TABLE 51 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 72

TABLE 52 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY , BY REGION, 2020–2027 (USD MILLION) 72

TABLE 53 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 72

TABLE 54 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 55 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 56 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 57 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74

TABLE 58 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2020–2027 (USD MILLION) 74

TABLE 59 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75

TABLE 60 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2020–2027 (USD MILLION) 75

TABLE 61 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 77

TABLE 62 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2020–2027 (USD MILLION) 78

TABLE 63 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78

TABLE 64 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2020–2027 (USD MILLION) 78

TABLE 65 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020–2027 (USD MILLION) 79

TABLE 66 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020–2027 (USD MILLION) 79

TABLE 67 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80

TABLE 68 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020–2027 (USD MILLION) 80

TABLE 69 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 80

TABLE 70 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020–2027 (USD MILLION) 81

TABLE 71 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81

TABLE 72 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2020–2027 (USD MILLION) 81

TABLE 73 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82

TABLE 74 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 82

TABLE 75 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83

TABLE 76 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 83

TABLE 77 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION, BY REGION, 2020–2027 (USD MILLION) 83

TABLE 78 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION , BY REGION, 2020–2027 (USD MILLION) 84

TABLE 79 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY , BY REGION, 2020–2027 (USD MILLION) 84

TABLE 80 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY, BY REGION, 2020–2027 (USD MILLION) 84

TABLE 81 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85

TABLE 82 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2020–2027 (USD MILLION) 85

TABLE 83 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 85

TABLE 84 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2020–2027 (USD MILLION) 86

TABLE 85 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88

TABLE 86 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 88

TABLE 87 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89

TABLE 88 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 89

TABLE 89 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 90

TABLE 90 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS , BY REGION, 2020–2027 (USD MILLION) 90

TABLE 91 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020 2027 (USD MILLION) 91

TABLE 92 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2020–2027 (USD MILLION) 91

TABLE 93 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 93

TABLE 94 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 93

TABLE 95 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 96 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 97 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 95

TABLE 98 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 95

TABLE 99 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 95

TABLE 100 GLOBAL NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 96

TABLE 101 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 96

TABLE 102 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 96

TABLE 103 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 97

TABLE 104 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 97

TABLE 105 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 97

TABLE 106 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 98

TABLE 107 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 98

TABLE 108 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 98

TABLE 109 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 99

TABLE 110 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 99

TABLE 111 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 99

TABLE 112 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 100

TABLE 113 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 100

TABLE 114 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 100

TABLE 115 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 101

TABLE 116 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 101

TABLE 117 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 101

TABLE 118 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 102

TABLE 119 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 102

TABLE 120 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 102

TABLE 121 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 103

TABLE 122 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 103

TABLE 123 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 104

TABLE 124 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 104

TABLE 125 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 104

TABLE 126 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 105

TABLE 127 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 105

TABLE 128 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 105

TABLE 129 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 106

TABLE 130 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 106

TABLE 131 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 106

TABLE 132 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 106

TABLE 133 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 107

TABLE 134 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 107

TABLE 135 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 107

TABLE 136 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 108

TABLE 137 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 108

TABLE 138 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 108

TABLE 139 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 109

TABLE 140 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 109

TABLE 141 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 109

TABLE 142 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 110

TABLE 143 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 110

TABLE 144 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 110

TABLE 145 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 111

TABLE 146 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 111

TABLE 147 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 111

TABLE 148 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 112

TABLE 149 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 112

TABLE 150 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 112

TABLE 151 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 113

TABLE 152 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 114

TABLE 153 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 154 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 155 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 115

TABLE 156 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 115

TABLE 157 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 115

TABLE 158 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 116

TABLE 159 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 116

TABLE 160 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 116

TABLE 161 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 117

TABLE 162 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 117

TABLE 163 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 117

TABLE 164 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 118

TABLE 165 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 118

TABLE 166 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 118

TABLE 167 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 119

TABLE 168 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 119

TABLE 169 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 119

TABLE 170 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 120

TABLE 171 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 120

TABLE 172 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 120

TABLE 173 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 121

TABLE 174 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 121

TABLE 175 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 121

TABLE 176 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 122

TABLE 177 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 122

TABLE 178 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 122

TABLE 179 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 123

TABLE 180 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 123

TABLE 181 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 123

TABLE 182 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 124

TABLE 183 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 124

TABLE 184 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 124

TABLE 185 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 125

TABLE 186 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 125

TABLE 187 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 125

TABLE 188 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 125

TABLE 189 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 126

TABLE 190 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 126

TABLE 191 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 126

TABLE 192 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 127

TABLE 193 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 127

TABLE 194 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 127

TABLE 195 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 128

TABLE 196 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 128

TABLE 197 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 128

TABLE 198 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 129

TABLE 199 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 129

TABLE 200 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 129

TABLE 201 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 130

TABLE 202 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 130

TABLE 203 U.S. AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 130

TABLE 204 U.S. AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 131

TABLE 205 CANADA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 131

TABLE 206 CANADA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 131

TABLE 207 CANADA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 132

TABLE 208 CANADA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 132

TABLE 209 CANADA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 132

TABLE 210 CANADA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 133

TABLE 211 CANADA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 133

TABLE 212 CANADA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 133

TABLE 213 CANADA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 134

TABLE 214 CANADA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 134

TABLE 215 CANADA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 134

TABLE 216 CANADA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 135

TABLE 217 CANADA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 135

TABLE 218 CANADA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 135

TABLE 219 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 136

TABLE 220 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 136

TABLE 221 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 136

TABLE 222 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 137

TABLE 223 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 137

TABLE 224 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 137

TABLE 225 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 138

TABLE 226 CANADA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 138

TABLE 227 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 138

TABLE 228 CANADA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 139

TABLE 229 CANADA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 139

TABLE 230 CANADA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 139

TABLE 231 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 140

TABLE 232 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 140

TABLE 233 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 140

TABLE 234 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 141

TABLE 235 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 141

TABLE 236 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2020-2027 (USD MILLION) 141

TABLE 237 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 142

TABLE 238 SOUTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2020-2027 (USD MILLION) 142

TABLE 239 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 142

TABLE 240 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 143

TABLE 241 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 143

TABLE 242 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 143

TABLE 243 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 143

TABLE 244 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2020-2027 (USD MILLION) 144

TABLE 245 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 144

TABLE 246 SOUTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 144

TABLE 247 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 145

TABLE 248 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2020-2027 (USD MILLION) 145

TABLE 249 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 145

TABLE 250 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2020-2027 (USD MILLION) 146

TABLE 251 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 146

TABLE 252 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 146

TABLE 253 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 147

TABLE 254 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 147

TABLE 255 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 147

TABLE 256 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 148

TABLE 257 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 148

TABLE 258 SOUTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2020-2027 (USD MILLION) 148

TABLE 259 EUROPE AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 149

TABLE 260 EUROPE AVASCULAR NECROSIS MARKET, BY REGION, 2020-2027 (USD MILLION) 149

TABLE 261 . EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 149

TABLE 262 EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 150

TABLE 263 EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 150

TABLE 264 EUROPE AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 151

TABLE 265 EUROPE AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 151

TABLE 266 EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 151

TABLE 267 EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 152

TABLE 268 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 152

TABLE 269 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 152

TABLE 270 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 153

TABLE 271 EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 153

TABLE 272 EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 153

TABLE 273 EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 154

TABLE 274 EUROPE AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 154

TABLE 275 EUROPE AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 154

TABLE 276 EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 155

TABLE 277 EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 155

TABLE 278 EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 155

TABLE 279 EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 156

TABLE 280 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 156

TABLE 281 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 156

TABLE 282 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 157

TABLE 283 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 157

TABLE 284 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 157

TABLE 285 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 158

TABLE 286 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 158

TABLE 287 EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 158

TABLE 288 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 159

TABLE 289 EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 159

TABLE 290 EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 159

TABLE 291 EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 160

TABLE 292 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 160

TABLE 293 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 160

TABLE 294 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 161

TABLE 295 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 161

TABLE 296 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 161

TABLE 297 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 162

TABLE 298 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 162

TABLE 299 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 162

TABLE 300 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 163

17 List Of Tables

TABLE 301 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 163

TABLE 302 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 163

TABLE 303 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 164

TABLE 304 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 164

TABLE 305 WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 165

TABLE 306 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 165

TABLE 307 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 165

TABLE 308 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 166

TABLE 309 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 166

TABLE 310 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 166

TABLE 311 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 167

TABLE 312 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 167

TABLE 313 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 167

TABLE 314 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 168

TABLE 315 WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 168

TABLE 316 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 168

TABLE 317 WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 169

TABLE 318 GERMANY AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 170

TABLE 319 GERMANY AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 170

TABLE 320 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 170

TABLE 321 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 171

TABLE 322 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 171

TABLE 323 GERMANY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 171

TABLE 324 GERMANY AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 172

TABLE 325 GERMANY AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 172

TABLE 326 GERMANY AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 172

TABLE 327 GERMANY AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 172

TABLE 328 GERMANY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 173

TABLE 329 GERMANY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 173

TABLE 330 GERMANY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 173

TABLE 331 GERMANY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 174

TABLE 332 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 174

TABLE 333 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 174

TABLE 334 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 175

TABLE 335 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 175

TABLE 336 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 175

TABLE 337 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 176

TABLE 338 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 176

TABLE 339 GERMANY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 176

TABLE 340 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 177

TABLE 341 GERMANY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 177

TABLE 342 GERMANY AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 177

TABLE 343 GERMANY AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 178

TABLE 344 FRANCE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 179

TABLE 345 FRANCE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 179

TABLE 346 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 179

TABLE 347 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 180

TABLE 348 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 180

TABLE 349 FRANCE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 180

TABLE 350 FRANCE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 181

TABLE 351 FRANCE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 181

TABLE 352 FRANCE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 181

TABLE 353 FRANCE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 181

TABLE 354 FRANCE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 182

TABLE 355 FRANCE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 182

TABLE 356 FRANCE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 182

TABLE 357 FRANCE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 183

TABLE 358 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 183

TABLE 359 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 183

TABLE 360 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 184

TABLE 361 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 184

TABLE 362 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 184

TABLE 363 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 185

TABLE 364 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 185

TABLE 365 FRANCE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 185

TABLE 366 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 186

TABLE 367 FRANCE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 186

TABLE 368 FRANCE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 186

TABLE 369 FRANCE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 187

TABLE 370 UK AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 188

TABLE 371 UK AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 188

TABLE 372 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 188

TABLE 373 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 189

TABLE 374 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 189

TABLE 375 UK AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 189

TABLE 376 UK AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 190

TABLE 377 UK AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 190

TABLE 378 UK AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 190

TABLE 379 UK AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 190

TABLE 380 UK AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 191

TABLE 381 UK AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 191

TABLE 382 UK AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 191

TABLE 383 UK AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 192

TABLE 384 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 192

TABLE 385 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 192

TABLE 386 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 193

TABLE 387 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 193

TABLE 388 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 193

TABLE 389 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 194

TABLE 390 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 194

TABLE 391 UK AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 194

TABLE 392 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 195

TABLE 393 UK AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 195

TABLE 394 UK AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 195

TABLE 395 UK AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 196

TABLE 396 ITALY AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 197

TABLE 397 ITALY AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 197

TABLE 398 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 197

TABLE 399 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 198

TABLE 400 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 198

TABLE 401 ITALY AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 198

TABLE 402 ITALY AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 199

TABLE 403 ITALY AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 199

TABLE 404 ITALY AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 199

TABLE 405 ITALY AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 199

TABLE 406 ITALY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 200

TABLE 407 ITALY AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 200

TABLE 408 ITALY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 200

TABLE 409 ITALY AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 201

TABLE 410 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 201

TABLE 411 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 201

TABLE 412 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 202

TABLE 413 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 202

TABLE 414 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 202

TABLE 415 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 203

TABLE 416 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 203

TABLE 417 ITALY AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 203

TABLE 418 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 204

TABLE 419 ITALY AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 204

TABLE 420 ITALY AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 204

TABLE 421 ITALY AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 205

TABLE 422 SPAIN AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 206

TABLE 423 SPAIN AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 206

TABLE 424 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 206

TABLE 425 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 207

TABLE 426 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 207

TABLE 427 SPAIN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 207

TABLE 428 SPAIN AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 208

TABLE 429 SPAIN AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 208

TABLE 430 SPAIN AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 208

TABLE 431 SPAIN AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 208

TABLE 432 SPAIN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 209

TABLE 433 SPAIN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 209

TABLE 434 SPAIN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 209

TABLE 435 SPAIN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 210

TABLE 436 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 210

TABLE 437 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 210

TABLE 438 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 211

TABLE 439 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 211

TABLE 440 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 211

TABLE 441 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 212

TABLE 442 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 212

TABLE 443 SPAIN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 212

TABLE 444 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 213

TABLE 445 SPAIN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 213

TABLE 446 SPAIN AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 213

TABLE 447 SPAIN AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 214

TABLE 448 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 215

TABLE 449 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 215

TABLE 450 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 215

TABLE 451 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 216

TABLE 452 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 216

TABLE 453 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 216

TABLE 454 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 217

TABLE 455 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 217

TABLE 456 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 217

TABLE 457 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 217

TABLE 458 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 218

TABLE 459 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 218

TABLE 460 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 218

TABLE 461 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 219

TABLE 462 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 219

TABLE 463 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 219

TABLE 464 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 220

TABLE 465 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 220

TABLE 466 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 220

TABLE 467 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 221

TABLE 468 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 221

TABLE 469 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 221

TABLE 470 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 222

TABLE 471 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 222

TABLE 472 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 222

TABLE 473 REST OF WESTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 223

TABLE 474 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 224

TABLE 475 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 224

TABLE 476 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 224

TABLE 477 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 225

TABLE 478 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 225

TABLE 479 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 225

TABLE 480 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 226

TABLE 481 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 226

TABLE 482 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 226

TABLE 483 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 226

TABLE 484 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 227

TABLE 485 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 227

TABLE 486 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 227

TABLE 487 EASTERN EUROPE AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 228

TABLE 488 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 228

TABLE 489 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 228

TABLE 490 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 229

TABLE 491 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 229

TABLE 492 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 229

TABLE 493 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 230

TABLE 494 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 230

TABLE 495 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 230

TABLE 496 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 231

TABLE 497 EASTERN EUROPE AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 231

TABLE 498 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 231

TABLE 499 EASTERN EUROPE AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 232

TABLE 500 . ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 232

TABLE 501 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 232

TABLE 502 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 233

TABLE 503 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 233

TABLE 504 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 234

TABLE 505 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 234

TABLE 506 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 234

TABLE 507 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 235

TABLE 508 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 235

TABLE 509 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 235

TABLE 510 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 236

TABLE 511 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 236

TABLE 512 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 236

TABLE 513 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 237

TABLE 514 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 237

TABLE 515 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 237

TABLE 516 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 238

TABLE 517 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 238

TABLE 518 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 238

TABLE 519 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 239

TABLE 520 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 239

TABLE 521 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 239

TABLE 522 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 240

TABLE 523 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 240

TABLE 524 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 240

TABLE 525 ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 241

TABLE 526 ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 241

TABLE 527 ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 241

TABLE 528 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 242

TABLE 529 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 242

TABLE 530 . JAPAN AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 243

TABLE 531 JAPAN AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 243

TABLE 532 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 243

TABLE 533 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 244

TABLE 534 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 244

TABLE 535 JAPAN AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 244

TABLE 536 JAPAN AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 245

TABLE 537 JAPAN AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 245

TABLE 538 JAPAN AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 245

TABLE 539 JAPAN AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 245

TABLE 540 JAPAN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 246

TABLE 541 JAPAN AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 246

TABLE 542 JAPAN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 246

TABLE 543 JAPAN AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 247

TABLE 544 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 247

TABLE 545 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 247

TABLE 546 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 248

TABLE 547 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 248

TABLE 548 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 248

TABLE 549 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 249

TABLE 550 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 249

TABLE 551 JAPAN AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 249

TABLE 552 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 250

TABLE 553 JAPAN AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 250

TABLE 554 JAPAN AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 250

TABLE 555 JAPAN AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 251

TABLE 556 .CHINA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 251

TABLE 557 CHINA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 251

TABLE 558 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 252

TABLE 559 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 252

TABLE 560 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 252

TABLE 561 CHINA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 253

TABLE 562 CHINA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 253

TABLE 563 CHINA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 253

TABLE 564 CHINA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 254

TABLE 565 CHINA AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 254

TABLE 566 CHINA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 254

TABLE 567 CHINA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 255

TABLE 568 CHINA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 255

TABLE 569 CHINA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 255

TABLE 570 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 256

TABLE 571 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 256

TABLE 572 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 256

TABLE 573 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 257

TABLE 574 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 257

TABLE 575 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 257

TABLE 576 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 258

TABLE 577 CHINA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 258

TABLE 578 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 258

TABLE 579 CHINA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 259

TABLE 580 CHINA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 259

TABLE 581 CHINA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 259

TABLE 582 .INDIA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 260

TABLE 583 INDIA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 260

TABLE 584 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 260

TABLE 585 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 261

TABLE 586 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 261

TABLE 587 INDIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 261

TABLE 588 INDIA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 262

TABLE 589 INDIA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 262

TABLE 590 INDIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 262

TABLE 591 INDIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS,, 2020-2027 (USD MILLION) 262

TABLE 592 INDIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 263

TABLE 593 INDIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 263

TABLE 594 INDIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 263

TABLE 595 INDIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 264

TABLE 596 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 264

TABLE 597 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 264

TABLE 598 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 265

TABLE 599 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 265

TABLE 600 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 265

18 List Of Tables

TABLE 601 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 266

TABLE 602 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 266

TABLE 603 INDIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 266

TABLE 604 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 267

TABLE 605 INDIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 267

TABLE 606 INDIA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 267

TABLE 607 INDIA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 268

TABLE 608 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 268

TABLE 609 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 268

TABLE 610 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 269

TABLE 611 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 269

TABLE 612 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 269

TABLE 613 AUSTRALIA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 270

TABLE 614 AUSTRALIA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 270

TABLE 615 AUSTRALIA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 270

TABLE 616 AUSTRALIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 271

TABLE 617 AUSTRALIA AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2020-2027 (USD MILLION) 271

TABLE 618 AUSTRALIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 271

TABLE 619 AUSTRALIA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 272

TABLE 620 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 272

TABLE 621 AUSTRALIA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 272

TABLE 622 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 273

TABLE 623 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 273

TABLE 624 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 273

TABLE 625 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 274

TABLE 626 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 274

TABLE 627 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 274

TABLE 628 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 275

TABLE 629 AUSTRALIA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 275

TABLE 630 AUSTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 275

TABLE 631 USTRALIA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 276

TABLE 632 AUSTRALIA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 276

TABLE 633 AUSTRALIA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 276

TABLE 634 .REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 277

TABLE 635 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 277

TABLE 636 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 277

TABLE 637 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 278

TABLE 638 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 278

TABLE 639 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 278

TABLE 640 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 279

TABLE 641 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 279

TABLE 642 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 279

TABLE 643 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 279

TABLE 644 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 280

TABLE 645 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 280

TABLE 646 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 280

TABLE 647 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 281

TABLE 648 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 281

TABLE 649 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 281

TABLE 650 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 282

TABLE 651 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 282

TABLE 652 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 282

TABLE 653 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 283

TABLE 654 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 283

TABLE 655 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 283

TABLE 656 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 284

TABLE 657 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 284

TABLE 658 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 284

TABLE 659 REPUBLIC OF KOREA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 285

TABLE 660 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 285

TABLE 661 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 285

TABLE 662 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 286

TABLE 663 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 286

TABLE 664 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 286

TABLE 665 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 287

TABLE 666 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 287

TABLE 667 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 287

TABLE 668 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 288

TABLE 669 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 288

TABLE 670 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 288

TABLE 671 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 289

TABLE 672 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 289

TABLE 673 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 289

TABLE 674 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 290

TABLE 675 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 290

TABLE 676 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 290

TABLE 677 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 291

TABLE 678 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 291

TABLE 679 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 291

TABLE 680 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 292

TABLE 681 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 292

TABLE 682 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 292

TABLE 683 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 293

TABLE 684 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 293

TABLE 685 REST OF ASIA PACIFIC AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 293

TABLE 686 . MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 294

TABLE 687 MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 294

TABLE 688 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 295

TABLE 689 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 295

TABLE 690 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 295

TABLE 691 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 296

TABLE 692 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 296

TABLE 693 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 296

TABLE 694 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 297

TABLE 695 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 297

TABLE 696 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 297

TABLE 697 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 297

TABLE 698 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 298

TABLE 699 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 298

TABLE 700 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 298

TABLE 701 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 299

TABLE 702 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 299

TABLE 703 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 299

TABLE 704 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 300

TABLE 705 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 300

TABLE 706 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 300

TABLE 707 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 301

TABLE 708 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 301

TABLE 709 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 301

TABLE 710 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 302

TABLE 711 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 302

TABLE 712 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 302

TABLE 713 MIDDLE EAST AND AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 303

TABLE 714 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 303

TABLE 715 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 303

TABLE 716 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 304

TABLE 717 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 304

TABLE 718 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 305

TABLE 719 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 305

TABLE 720 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 305

TABLE 721 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 306

TABLE 722 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 306

TABLE 723 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 307

TABLE 724 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 307

TABLE 725 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 307

TABLE 726 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 307

TABLE 727 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING,, 2020-2027 (USD MILLION) 308

TABLE 728 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 308

TABLE 729 MIDDLE EAST AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 308

TABLE 730 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 309

TABLE 731 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 309

TABLE 732 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 309

TABLE 733 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 310

TABLE 734 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 310

TABLE 735 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 310

TABLE 736 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 311

TABLE 737 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 311

TABLE 738 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 311

TABLE 739 MIDDLE EAST AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 312

TABLE 740 MIDDLE EAST AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 312

TABLE 741 MIDDLE EAST AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 312

TABLE 742 AFRICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 313

TABLE 743 AFRICA AVASCULAR NECROSIS MARKET, BY VOLUME/PROCEDURES, 2020-2027 313

TABLE 744 .AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 314

TABLE 745 AFRICA AVASCULAR NECROSIS MARKET, BY TYPE, 2020-2027 (USD MILLION) 314

TABLE 746 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 314

TABLE 747 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY AGE GROUP, 2020-2027 (USD MILLION) 315

TABLE 748 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 315

TABLE 749 AFRICA AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVN, BY CAUSES, 2020-2027 (USD MILLION) 315

TABLE 750 AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 316

TABLE 751 AFRICA AVASCULAR NECROSIS MARKET, BY SITE, 2020-2027 (USD MILLION) 316

TABLE 752 AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 316

TABLE 753 AFRICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION) 316

TABLE 754 AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 317

TABLE 755 AFRICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS BY IMAGING, 2020-2027 (USD MILLION) 317

TABLE 756 AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 317

TABLE 757 AFRICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2020-2027 (USD MILLION) 318

TABLE 758 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION, 2020-2027 (USD MILLION) 318

TABLE 759 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY MEDICATION,, 2020-2027 (USD MILLION) 318

TABLE 760 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 319

TABLE 761 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2020-2027 (USD MILLION) 319

TABLE 762 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 319

TABLE 763 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2020-2027 (USD MILLION) 320

TABLE 764 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 320

TABLE 765 AFRICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2020-2027 (USD MILLION) 320

TABLE 766 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 321

TABLE 767 AFRICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2020-2027 (USD MILLION) 321

TABLE 768 AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 321

TABLE 769 AFRICA AVASCULAR NECROSIS MARKET BY END-USER, 2020-2027 (USD MILLION) 322

TABLE 770 GLOBAL AVASCULAR NECROSIS MARKET: KEY DEVELOPMENT 326

19 List Of Figures

FIGURE 1 GLOBAL AVASCULAR NECROSIS MARKET: MARKET STRUCTURE 33

FIGURE 2 RESEARCH PROCESS OF MRFR 35

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 38

FIGURE 4 DRO OF GLOBAL AVASCULAR NECROSIS MARKET 40

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AVASCULAR NECROSIS MARKET 46

FIGURE 6 SUPPLY CHAIN: AVASCULAR NECROSIS MARKET 48

FIGURE 7 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2010, 2020, 2027 (USD MILLION) 55

FIGURE 8 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2010, 2020, 2027 (USD MILLION) 64

FIGURE 9 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS 2010, 2020, 2027 (USD MILLION) 69

FIGURE 10 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT 2010, 2020, 2027 (USD MILLIONS) 77

FIGURE 11 GLOBAL AVASCULAR NECROSIS MARKET, BY END-USER 2010, 2020, 2027 (USD MILLION) 88

FIGURE 12 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020 & 2027 (USD MILLION) 94

FIGURE 13 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020 & 2027 (USD MILLION) 103

FIGURE 14 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2020, 2027 (USD MILLION) 113

FIGURE 15 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2027 (USD MILLION) 233

FIGURE 16 MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2027 (USD MILLION) 294

FIGURE 17 GLOBAL AVASCULAR NECROSIS MARKET, MARKET SHARE ANALYSIS 2020 (%) 324

FIGURE 18 GLOBAL AVASCULAR NECROSIS MARKET COMPETITIVE LANDSCAPE (%) 325

Global Avascular Necrosis Market: Competitive Landscape


Stryker Corporation, Ethicon Inc., Medtronic plc, Merck KGaA, Boehringer Ingelheim GmbH collectively accounted for more than 22% of the market share of the global avascular necrosis market in 2016. These companies continue to retain their strong global presence through expansion, merger & acquisition, and extensive product portfolio.


Stryker Corporation has a significant product portfolio for bone grafts including the products like Vitoss, HydroSet, and Cortoss, etc. Stryker Corporation accounted for more than 10% of the market share in avascular necrosis market in 2017. The company has a wide geographic presence and also the strong sales & distribution network which has helped the company gain its position in the market. For instance, the Stryker Corporation, to enhance its business, acquired companies such as Novadaq Technologies Inc. in 2017, Stanmore Implants Worldwide Limited, Physio-Control International Inc, & Vertebral compression fracture portfolio from BD in 2016; and some other companies in the recent past.


Medtronic, Inc. manufactures and sells device-based medical therapies. The company holds the second position in terms of market share in 2017. The company manufactures image-guided surgery and intra-operative imaging systems. Its products include electrophysiology catheters, and implantable neurostimulation therapies; and drug delivery systems for the treatment of chronic pain, and other disorders.


Ethicon Inc. is a subsidiary of Johnson & Johnson Inc. The company acquired the third spot in the market. The company is an American multinational, fortune 500, medical devices, pharmaceutical and consumer packaged goods manufacturing company functioning in manufacturing, marketing, and selling of consumer healthcare products across the globe. The company's major franchises in the pharmaceutical segment include immunology, neuroscience, infectious disease, and oncology. They have 250 subsidiary companies which operations in 60 countries and products sold in over 175 countries. 


Boehringer Ingelheim GmbH stood at the 7th position in the global avascular necrosis market. The company develops, manufactures, and markets human and veterinary pharmaceutical products in Germany and internationally. They are focusing on highly dynamic research fields such as immune modulation and regenerative medicine which have created impact and created synergies among several of their therapeutic areas.


Pfizer, Inc. held a prominent position in terms of market share for therapeutics in 2017. Its major focus is on the acquisition of various companies such as Medivation Inc., small molecule division of AstraZeneca, Anacor, and Hospira. The company is a leading research-based biopharmaceutical organization which develops medicines and vaccines for a wide range of medical disciplines such as immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. Pfizer operates in countries such as Germany, France, Greece, Korea, Mexico, Russia, the Netherlands, India, Poland, Turkey, Israel, China, and others.


Sanofi SA is focusing on its huge and innovative product pipeline which includes 37 new molecular entities and novel vaccines. The company offers drugs, generic medicines, food supplements, and cosmetics, as well as provide medical devices for cancer, cardiology, gynecology, and diabetes. Sanofi serves customers worldwide with a presence in more than 100 countries and industrial sites in 38 countries.


In the global avascular necrosis market, more than 200 companies are involved in the manufacturing of the various types of catheters, surgical devices, and drugs. Hence, the market is not completely dominated by any one or two players but fairly divided among the top drug and medical device manufacturing companies. Many leading players are focusing on the Americas and European markets owing to well-established markets, huge patient population, and high healthcare expenditures. These players have expanded their market in other regions as well. Major companies have a huge brand identity and product portfolio. These companies have adopted the organic strategy of product launches and acquisitions to gain the market. These strategies implied by the players in this market is continuous innovation and development of the new and better products to beat the opponents and strive in this big market.